

PRESS RELEASE

Lelystad, the Netherlands, 13 May 2011

Further explanation agenda item 5 (extra dividend distribution) of the annual General Meeting of Shareholders to be held on 13 May 2011

Fornix BioSciences N.V. (NYSE Euronext: AFORBI) announces the following in relation to item 5 of the agenda for the coming annual General Meeting of Shareholders (AGM) to be held on 13 May 2011.

As thoroughly discussed during the Extraordinary General Meeting of Shareholders (EGM) held on 30 March 2011, Fornix is considering distributing part of its freely distributable reserves as "extra dividend". During the aforementioned EGM shareholders expressed the explicit desire to have the distribution of this extra dividend included as a voting item on the agenda of the AGM to be held on 13 May 2011. In accordance with the articles of association, a distribution of interim dividend can take place pursuant to a proposal of the Management Board that has been approved by the Supervisory Board. Taking the request of the shareholders into consideration, the Management Board and Supervisory Board wish to submit the proposal for the distribution of extra dividend to the EGM for a vote.

In view of the above, taking into consideration the ongoing obligations and reserves to be maintained in order to meet contingent liabilities arising out of provided guarantees and indemnifications, at the upcoming AGM to be held on 13 May 2011, with respect to agenda item 5, the Management Board and the Supervisory Board will submit to the shareholders of Fornix for approval, the proposed resolution of the Management Board and the Supervisory Board to distribute in July 2011 an interim dividend of EUR 0.91 per share out of the freely distributable reserves, on the condition that no claim has been made under the guarantees and indemnities.

After the aforementioned interim dividend distribution has taken place, the Management Board currently sees room for an additional interim dividend of EUR 0.21 per share in January 2012.

END OF PRESS RELEASE

For additional information: Fornix BioSciences N.V.

C.L. Bergman

CEO

Tel. (0320) 26 77 99

<http://www.fornix.nl/>